Cargando…
Heart failure: an update from the last years and a look at the near future
In the last years, major progress occurred in heart failure (HF) management. Quadruple therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst verciguat is becoming available across several countries, omecamtiv mecarbil is waiting to be released for clinical use....
Autores principales: | Riccardi, Mauro, Sammartino, Antonio Maria, Piepoli, Massimo, Adamo, Marianna, Pagnesi, Matteo, Rosano, Giuseppe, Metra, Marco, von Haehling, Stephan, Tomasoni, Daniela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773737/ https://www.ncbi.nlm.nih.gov/pubmed/36546712 http://dx.doi.org/10.1002/ehf2.14257 |
Ejemplares similares
-
Heart failure in the last year: progress and perspective
por: Tomasoni, Daniela, et al.
Publicado: (2020) -
Device-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction
por: Riccardi, Mauro, et al.
Publicado: (2022) -
Advanced heart failure: guideline‐directed medical therapy, diuretics, inotropes, and palliative care
por: Tomasoni, Daniela, et al.
Publicado: (2022) -
A year in heart failure: an update of recent findings
por: Stretti, Lorenzo, et al.
Publicado: (2021) -
A year in heart failure: updates of clinical and preclinical findings
por: Bäck, Magnus, et al.
Publicado: (2023)